Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
336.95 K
Value Traded
12.19 M
Short % Float
111.87%
-13.22%Week
-36.82%1 Month
-37.65%3 Month
-37.65%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.67 B
EPS (TTM)
-
P/E Ratio
-
Ent. Value
1.55 B
Total Shares
90.05 M
Float Shares
2.20 M
Insiders
97.56%
Institutions
-
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
BRVE Catalyst Timeline
Dated clinical, regulatory and corporate events for Braveheart Bio, Inc. Common Stock
Catalyst Timeline
Dated clinical, regulatory & corporate events for Braveheart Bio, Inc. Common Stock
26Total events
6Upcoming
7Tier-1 (high impact)
2026 to 2029Coverage
Upcoming catalysts 2
Event history 16
●Trial InitiationBHB-1893Trial
LIONHEART-HCM Phase 3 trial initiated
obstructive hypertrophic cardiomyopathy (oHCM)source ↗
▲IND ClearanceBHB-1893IND
Active U.S. IND for nHCM program
non-obstructive hypertrophic cardiomyopathy (nHCM)source ↗
●Trial InitiationBHB-1893Trial
Phase 3 LIONHEART-HCM Trial of BHB-1893 in oHCM Initiated
Obstructive Hypertrophic Cardiomyopathy (oHCM)source ↗
▲Oral PresentationBHB-1893Presentation
Phase 2 results presented at HFA-ESC 2026
non-obstructive hypertrophic cardiomyopathy (nHCM)source ↗
▲Full ResultsBHB-1893Clinical Data
Phase 2 results announced in nHCM
non-obstructive hypertrophic cardiomyopathy (nHCM)source ↗
▲Topline ReadoutBHB-1893Clinical Data
Phase 2 trial results of HRS/BHB-1893 in nHCM announced
Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)source ↗
▲Late-BreakerBHB-1893Presentation
Phase 2 nHCM results for HRS/BHB-1893 featured in late-breaking presentation at 2026 HFA-ESC annual meeting
Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)source ↗
●Equity OfferingCorporate
Third closing of Series A preferred stock financing for $60.0 million
▲Topline ReadoutBHB-1893Clinical Data
Phase 2 oHCM results for BHB-1893 announced in March 2026
Obstructive Hypertrophic Cardiomyopathy (oHCM)source ↗
▲Late-BreakerBHB-1893Presentation
Late-breaking presentation of Phase 2 nHCM results at HFA-ESC 2026
Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)source ↗
Past FDA Catalysts and PDUFA Decisions
How BRVE actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every BRVE program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Forbion Growth Opportunities Fund III Cooperatief U.A.10% Owner | Buy | 1,920,000 11,640,546 held | $18.00 | 08/07/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BRVE
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in BRVE for Q2 2026. | ||||
BRVE Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BRVE ranks across every disease it competes in
Competitive Position is a premium feature
See how BRVE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBRVE News
-BRVE
Sep 16, 2026Braveheart Bio to Participate in Stifel Cardiometabolic Forum
Braveheart Bio, Inc. will participate in the Stifel Virtual Cardiometabolic Forum on September 30, 2026. The company's management will take part in a fireside chat at 12:30 p.m. EDT. The forum aims to highlight advancements in therapeutics for hypertrophic cardiomyopathy and other cardiovascular diseases.
Read more →-BRVE
Sep 8, 2026Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Braveheart Bio reported its Q2 2026 financial results, highlighting the initiation of the Phase 3 LIONHEART-HCM trial for BHB-1893 in obstructive hypertrophic cardiomyopathy (oHCM). The company has a strong cash position of $122.8 million, bolstered by its recent IPO, which is expected to support ongoing clinical programs. Additionally, they plan to initiate the NOBLEHEART-HCM Phase 3 study in non-obstructive HCM (nHCM) in 2027.
Read more →-BRVE
Sep 1, 2026Braveheart Bio to Participate in Cantor Global Healthcare Conference
Braveheart Bio, Inc. will participate in the Cantor Global Healthcare Conference from September 9-11, 2026. Management is scheduled for a fireside chat on September 10 at 3:20 p.m. EDT. The company focuses on developing next-generation therapeutics for hypertrophic cardiomyopathy and other cardiovascular diseases, with its lead candidate being BHB-1893.
Read more →-BRVE
Aug 7, 2026▼ -8.2%on this news
Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Braveheart Bio, Inc. has successfully closed its upsized initial public offering, raising $439.9 million by offering 24,437,500 shares at $18.00 each. The offering included the full exercise of the underwriters' option to purchase additional shares. The shares commenced trading on the Nasdaq Global Market on August 6, 2026, under the ticker symbol 'BRVE'.
Read more →-BRVE
Aug 6, 2026Braveheart Bio Announces Pricing of Upsized Initial Public Offering
Braveheart Bio, Inc. has announced the pricing of its upsized initial public offering, offering 21,250,000 shares at $18.00 each. The IPO is expected to raise approximately $382.5 million and will start trading on Nasdaq under the ticker BRVE on August 6, 2026. The offering is subject to customary closing conditions and includes an option for underwriters to purchase additional shares.
Read more →-BRVE
May 11, 2026Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Non-Obstructive Hypertrophic Cardiomyopathy
Hengrui Pharma and Braveheart Bio announced positive Phase 2 results for HRS/BHB-1893, a cardiac myosin inhibitor, in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). The treatment demonstrated rapid and sustained improvements in biomarkers, cardiac structure, and patient symptoms. The favorable safety profile supports further development of this potentially disease-modifying therapy.
Read more →-BRVE
Mar 30, 2026Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy
Hengrui Pharma and Braveheart Bio have announced positive results from a Phase 2 study of HRS/BHB-1893 for obstructive hypertrophic cardiomyopathy. The treatment demonstrated significant efficacy with rapid reductions in left ventricular outflow tract. The study suggests a best-in-class profile, emphasizing safety and ease of use with a simplified dosing regimen.
Read more →-BRVE
Mar 26, 2026Braveheart Bio Appoints Emil deGoma, M.D., as Chief Medical Officer
Braveheart Bio has appointed Emil deGoma, M.D., as Chief Medical Officer to lead clinical strategy and medical affairs. This appointment comes as the company prepares for a global pivotal trial of BHB-1893 in obstructive hypertrophic cardiomyopathy, aimed for initiation in 2026. DeGoma's extensive experience in cardiology and clinical trials is expected to bolster the company's efforts in developing innovative therapies.
Read more →-BRVE
Feb 23, 2026Braveheart Bio to Participate in TD Cowen 46th Annual Health Care Conference
Braveheart Bio will participate in the TD Cowen 46th Annual Health Care Conference from March 2-4, 2026, in Boston. The company aims to engage with investors through one-on-one meetings. Braveheart is focused on developing novel therapeutics for hypertrophic cardiomyopathy and is advancing its candidate BHB-1893 in late-stage clinical trials.
Read more →-BRVE
Feb 5, 2026Braveheart Bio Announces Senior Leadership Appointments to Strengthen Scientific and Operational Capabilities While Advancing Global Phase 3 Development
Braveheart Bio has announced key leadership appointments, promoting Marc Evanchik to Chief Scientific Officer and hiring Brittany de Temple as Senior Vice President of Development Operations. These changes aim to bolster the company's capabilities as it prepares for a global Phase 3 trial in obstructive hypertrophic cardiomyopathy set for 2026. The leadership team is focused on transforming care for patients with hypertrophic cardiomyopathy.
Read more →About Braveheart Bio, Inc. Common Stock
HeadquartersONE LETTERMAN DR., SAN FRANCISCO, CA, 94129
BIOPHARMAWATCH ELITE PLUS
Trade the next BRVE catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime